The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive (pneumococcal polysaccharide conjugate vaccine [21-valent]) intended to ...

Pfizer said it will 'support capacity-building initiatives, such as training healthcare professionals and advancing clinical ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

In that very special first year of a baby's life, harmful diseases such as pneumococcal pneumonia and measles can create ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

The Advisory Committee on Immunization Practices — an influential group of clinicians and scientists — recommends who should ...

In addition to increasing vaccine coverage in older adults, they need to monitor the changing epidemiology of pneumococcal serotypes ... funding from Wyeth/Pfizer, GSK, is a member of advisory ...

In that very special first year of a baby's life, harmful diseases such as pneumococcal pneumonia and measles can create serious, sometimes life-threatening infections. Pfizer's vaccine research ...

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...